Conditioning approaches such as radiotherapy or cytoablative regimens for immunosuppression are precluded. In fact, because of their potential teratogenic hazards the use of these agents is considered unwise.
unattainable by the existing techniques in the postnatal settings. The use of preimmune fetal cells as graft virtually eliminates the possibility of graft-versus-host disease (GVHD), a major problem in the postnatal setting. Conversely, the use of preimmune fetus as the recipient, permits transplantation across the immunologic barrier and even xenografts have now been Conditioning approaches such as radiotherapy or cytoablative regimens for immunosuppression are precluded. In fact, because of their potential teratogenic hazards the use of these agents is considered unwise.
The potential indications for in utero marrow transplantation are entirely different from those currently used in the postnatal settings. For instance, with the availability of molecular biology techniques for prenatal diagnosis of many genetic disorders, the possibility of in utero therapeutic intervention can now be realized via the introduction of hematopoietic cells that contain potentially functioning genes9-"
On the other hand, the practical impossibility of the use of conditioning regimens (radiotherapy and cytotoxic chemotherapy) poses a major problem in engraftment. In postnatal setting, such conditioning regimens deplete the recipient's endogenous pool of stem cells, thus permitting the engraftment of donor cells that may subsequently constitute the entire pool of stem cells in the chimeric organism. In the absence of conditioning regimens, grafted cells are in competition with the endogenous pool of stem cells. Early engraftment of a certain percentage of donor cells may occur, but this may be proportionally low, and, moreover, their stability cannot be fully achieved in the course of Thus, the proportion of donor cells decreases as gestation proceeds. Consequently, in the chimeric organism, only a fraction of the stem cell pool is made up of donor cells. Fortunately, in many of potential applications (eg, gene transfer) the total replacement of stem cell pool by donor cells may not be necessary. However, any factor that can give donor cells a competitive edge over the recipient's own stem cell may improve the efficiency of the technique.
The discovery of the molecular basis of selective homing in intravenously transplanted marrow cells12-17 has opened a new vista to manipulate the efficiency of grafting of hematopoietic stem cells. Our previous work in adult murine system showed that a brief ex vivo incubation of donor stem cells with a source of growth factors leads to upmodulation of homing receptors and enhanced efficiency of their engraftment.18 The latter effect may be related to the former.
In the present work, using fetal sheep and monkey models, we used a similar maneuver to enhance the efficiency of engraftment in the absence of cytoablative conditioning regimens. We now provide evidence that this simple method indeed leads to the enhancement of grafting during in utero transplantation and to the subsequent stability of the graft during the gestation period.
MATERIALS AND METHODS
Experimental animals. Time-dated, pregnant Dorset-Merino sheep (&is arks) pretyped at the P-globin locus as homozygous AA or BB were used in these studies. The sheep has two naturally occurring alleles at the P-globin locus (A and B) that direct the synthesis of types A (~~$ 3 2~) and B (a&B) hemoglobins that can be used as definitive markers of donor cell engraftment. HSC obtained from type A adult sheep were transplanted into type B Donor cellpreparation and transplantationprocedures. The studies were conducted in fetal sheep at 48 to 54 days of gestation (term, 145 days). Dorset Merino ewes (&is aries) with confirmed dates of conception were purchased from local suppliers and acclimatized for 10 days before donor cell infusion into the fetus. The microbubble technique used for the in utero transplantation of donor cells has been described previously.' Briefly, after a 48-hour fasting period, maternal ewes were sedated with ketamine 910 mg/kg, intramuscular), and received 0.5% to 1.0% halothaneoxygen mixture by inhalation via an endotracheal tube. The external jugular vein was cannulated for administration of fluids and antibiotics (penicillin, 2 million U; kanamycin, 400 mg). The uterus was exposed through a midline incision, and the myometrial layers were divided with electrocautery, leaving the amnion intact. The fetus was manipulated within the amniotic sac and, under direct visualization, donor cells (2 x lo9 cells/kg estimated fetal body weight in 0.5 to 1.0 mL) were injected into fetal peritoneal cavity. Uterine and maternal body walls were closed in layers and the ewes, after full recovery, were provided food and water ad libitum.
Fetal livers were obtained from preimmune fetal sheep ( < 6 0 days old; term, 145 days) and monkeys (59 to 68 days old; term, 165 days). Single cell suspensions were prepared by the passage of the liver tissue through a wet screen mesh (0.2 mm pore size) under a constant stream of medium composed of Iscove's modified Dulbec-CO'S medium (IMDM), and 10% fetal calf serum (FCS). The cell mixture was allowed to stand at room temperature for 5 minutes and the top two thirds of the cell suspension was removed, pelleted by centrifugation, and resuspended at the desired concentration in IMDM and 10% FCS.
Preparation of PHA-LCM. Phytohemagglutin-stimulated sheep leukocyte conditioned medium (PHA-LCM) was prepared by obtaining whole blood in heparinized, preservative-free containers. Red blood cells were sedimented with 6% betastarch for 1 hour at 37°C. This procedure was repeated thrice. BufTy coat was then collected and washed in equal volume of IMDM. The cells (500 x lo6) were then suspended in PHA-LCM basic mix (395 mL IMDM, 100 mL of FCS, 5 mL of PHA reconstituted in IMDM, and 5 mL of 1% L-glutamine) and the concentration was adjusted to 1 x 106/mL. Incubation was performed for 7 days under 5% C02.
The solution was then filtered and stored at 4°C until it was used. Donor cells were injected into recipient monkey fetuses through a 25-gauge spinal needle placed into the fetal peritoneal cavity under ultrasound guidance; the position of the needle was confirmed by visualization of microbubbles and intraperitoneal layering of fluid. Pregnancies were followed with weekly ultrasound until delivery. The sex of donor fetal sheep and monkeys was determined by anatomic dissection at the time of liver harvest. The sex of recipient sheep fetuses was determined visually at the time of donor cell injection and/or catheter emplacement. The sex of recipient monkey fetuses was determined before transplantation by chorionic villus sampling and direct preparation karyotype analysis or by ultrasound.
Sheep and monkey erythroid (CFU-E/BFU-E), myeloid (CFU-GM), and multipotent (CFU-
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Mix) hematopoietic progenitors were cultured in methylcellulose as d e~c r i b e d .~.~ The cells (2 to 4 X 105 cells/mL) were cultured in 0.9% methylcellulose in the presence of FCS (30%), IMDM, erythropoietin (1 U/mL), and a preparation of sheep/human PHA-LCM (5% vol/vol), and incubated at 37"C, 5% C02 in humidified air. Cultures were processed for karyotyping at day 9 of culture.3
All surviving recipients were examined for evidence of donor cell engraftment and GVHD at birth and at about monthly intervals thereafter. Peripheral blood and bone marrow aspirates were obtained from each animal for hemoglobin (sheep) and karyotype (sheep and monkeys) analyses. Peripheral blood cells and aliquots of bone marrow cells were analyzed for the presence of donor karyotype following PHA stimulation. The remaining bone marrow cells were cultured in methylcellulose in the presence of either erythropoietin or sheep/human PHA-LCM as described above. Cells from the culture plates on each series or isolated colonies were recovered by washing in IMDM, 20% FCS repeatedly until free of methylcellulose. The cells were then processed for karyotype analysis as de~cribed.2~
All transplantation recipients were observed for clinical signs of GVHD including loss of wool, diarrhea, and rhinorrhea. None of the newborn animals exhibited GVHD. The means and standard deviation of all measurements were subjected to Student's t test.
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RESULTS
While many growth factors are now purified and some are available in recombinant form, these are generally of human or murine origin. In our initial preliminary work, they proved to lack, in the usual concentrations, cross reactivity with sheep cells. Hence, we prepared conditioned medium from sheep lymphocytes stimulated with PHA-LCM. This conditioned medium had highly significant (P < .001) colony-stimulating activity for the growth of progenitor cells from fetal sheep liver in CFU-Mix, BFU-E, and CFU-GM assays (Fig  1) . Thus, conditioned medium from PHA-stimulated sheep lymphocytes was considered a rich source of necessary growth factors and could serve in these experiments. To
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show that the effect of PHA-LCM in sheep fetuses is indeed related to the presence of growth factors, some of these experiments were repeated in monkey fetuses as well, using recombinant growth factors (see below). Donor cells were incubated overnight (16 hours) with sheep PHA-LCM at 37°C and then were surgically transplanted into the recipient fetus. As shown in Fig 2 the proportion of donor cells that showed engraftment was always higher than fresh (unincubated) cells (P < .05) compared with both the control medium and fresh cells. The engraftment was lowest when incubation was performed under the same conditions (16 hours, 37°C) with culture medium only. This pattern was reproducibly seen not only in the proportion of donor cells as a fraction of all marrow cells differentially but also when engraftment was studied as lymphoid, myeloid, and erythroid cells.
Overall preincubation with PHA-LCM resulted in 59% 5 13% greater efficiency of donor cell engraftment (data from four separate samples after birth). In another set of experiments, we also examined the optimal time for ex vivo incubation of donor cells with PHA-LCM, and examined the percent of changes in donor cell engraftment. In this set of experiments (data not shown), the time of incubation varied from 4 to 48 hours with four animals in each group.
The engraftment increased to about 80% above the control level between 4 and 8 hours. It remained stable for 16 hours, after which time it began to decline, and by 48 hours it was no more than 50% above the control. Therefore. in all subsequent experiments 16-hour incubation was considered optimal. This pattern was stable for at least 300 days after transplantation (Fig 3) .
Effect of sheep PHA-LCM on fetal liver progenitors in vitro. The lower engraftment data for donor cells incubated with the culture medium only compared to fresh cells led us to examine the effect of ex vivo incubation of hematopoietic cells. The viability of all donor cells (as tested by trypan blue exclusion test) decreased as a function of time, reaching -30% after 48 hours (Fig 4) . Parallel to this decline was a decrease in the number of progenitors (as measured by progenitor cell assays), suggesting that cell death occurred when fetal sheep liver cells were incubated ex vivo in culture medium (Fig 4) . The decrease was significant at each point at P < .001.
Incubation in the presence of PHA-LCM significantly reduced this gradual decline in both the viability of marrow cells preparations and their content of progenitors so that after 16 hours neither viability nor progenitor cell numbers were significantly affected. After 48 hours viability was still greater than 70% and the number of progenitors was greater than 85%.
To study if the effect of PHA-LCM can be attributed to IL-3 and GM-CSF, we used recombinant human (rh) IL-3 and GM-CSF in a similar setting but now involving fetal monkey transplant. In contrast to sheep, rh materials are known to cross-react with monkey cells.
Liver cell suspensions were prepared from preimmune monkey fetus and incubated with rh GM-CSF (25 ng/mL) and rh IL-3 (15 ng/mL) for 16 hours. The cells (3 X 10s cells/kg) were then transplanted into preimmune monkey fetus and the newborn animals were examined for engraftment. The results are shown in Fig 5 . 
DISCUSSION
The data presented here indicate that the engraftment of fetal donor hematopoietic cells into fetal sheep and monkeys is enhanced by a simple maneuver that consists of a brief ex vivo incubation with a source of growth factors before transplantation. This is in agreement with our previous observations in adult murine systems,18 indicating that a similar maneuver leads to enhanced efficiency of engraftment of donor cells and thereby the number of cells required to reconstitute hematopoiesis after lethal irradiation can be reduced.
Data obtained in cloned murine progenitor cells indicated that this enhanced efficiency was probably attributable to upmodulation of the number of homing protein on the surface of progenitor cells. This upmodulation is cyclohexamide sensitive, indicating the requirement for de novo protein synthesis. Moreover, the rate of degradation of the protein on the surface is not affected.lg
A similar mechanism of upmodulation may be operative in fetal system, although cloned fetal progenitors are not available at this time to test this possibility.
Data from the murine system indicate IL-3 and GM-CSF as the two growth factors responsible for the enhanced efficiency of engraftment.ls Such other growth factors as IL-2 or erythropoietin do not affect the efficiency of engraftment. Because these factors from sheep are not available in purified or recombinant forms, and because murine and human IL-3 or GM-CSF do not cross-react with sheep cells, we used PHA-LCM which is a rich source of hematopoietic growth factors. It is reasonable to assume that in the sheep system, too, IL-3 and GM-CSF that are contained in PHA-LCM were responsible for the effect observed. This assumption is strengthened by our observation of fetal monkeys, using IL-3 and GM-CSF. These factors from human sources cross-react with monkey cells, and their ex vivo incubation with donor cells results in the enhancement of grafting efficiency.
It is of interest that, compared with fresh cells, the incubation of donor cells in the medium devoid of growth factors leads to a decrease in the viability of cells and the number of progenitor cells as measured by in vitro clonogenic assays. This is consistent with the current view that in the absence of hematopoietic growth factors progenitor cells tend to undergo apoptosis (programmed cell death) and a major mechanism of action for growth factor is to prevent apoptosis.') Thus, in the present work, the gradual decline in the viability and the number of progenitors could be reversed by incubation with growth factors.
The practical impossibility of the use of conditioning regimens (radiotherapy, cytoablative therapy) in fetal transplantation may not permit the depletion of homing sites from endogenous stem cells. This may erect a barrier that would prevent the expansion of donor progenitor cell pool in the recipient fetus. Under these circumstances donor cells would be diluted in the recipient's pool of progenitor cells and would have to compete with the latter cells to form only a proportion of the total stem cell pool. Any maneuver that gives donor cells a preferential competitive edge would improve the efficiency and applications of fetal hematopoietic cell transplantation. Brief ex vivo preincubation of donor cells with growth factors may constitute such a maneuver. It may lead to improved efficiency of engraftment, more stable graft, and, hence, it can expand the application of fetal hematopoietic cell transplantation.
